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The concept of preparing a special issue of Purinergic
Signalling to highlight progress in the medicinal chemistry
of purines arose during the 8th International Symposium on
Adenosine and Adenine Nucleotides, which was held in
Ferrara, Italy, from 24 May to 28 May 2006. This meeting
emphasized the accelerated pace of introduction of new
compounds, including preclinical and clinical candidates,
that act through purine-related mechanisms. The suggestion
to broaden the scope to include the intracellular actions of
purines, notably through protein kinases, was made by Dr.
Michael Williams, as an Associate Editor of this journal.
Consequently, this volume reveals new ligands for modula-
tion of the function of proteins that are involved in purine
action, encompassing both receptors and enzymes. This
purview could be described under the umbrella of the
“purinome,” which represents numerous critical interactions
in cellular function. Given the limited space available, we are
unable to effectively showcase all major aspects of the
purinome, but rather have provided representative segments.
The issue is written from the perspective of the medicinal
chemist but in a manner comprehensible to those in the
biological sciences. Both review chapters and original
chemical research reports are included in this volume. We
commend Prof. Geoff Burnstock, Editor in Chief of the
journal, for enthusiastically supporting the inclusion of a
dedicated issue on medicinal chemistry of purines and for
recognizing a central role played by medicinal chemistry in
the recent exponential growth of this field.
The protein targets of compounds in this volume include
twelveG protein-coupled receptors that respond to nucleosides
and nucleotides, i.e., both adenosine (four subtypes) and P2Y
receptors (eight subtypes), and seven nucleotide-gated ion
channels, i.e., P2X receptors. A chapter by Carroll et al.
reviews the P2X7 receptor. In addition, agonists (Baraldi et
al., Gao et al., Kim et al.), antagonists (Kalla and Zablocki),
and allosteric modulators (Göblyös and IJzerman) of the P1
family of adenosine receptors are described including
compounds currently under active development. It is to be
noted that at least four subtypes of the P2Y receptors are
activated by pyrimidine nucleotides (Jacobson et al.). Thus,
this issue is not exclusively limited to purines. These purine
and pyrimidine receptors are widespread in the body and
govern critical physiological processes, notably in the
immune, cardiovascular, skeletal-muscular, and nervous
systems. The volume also covers inhibition of the superfam-
ily of >500 kinases, which are involved in intracellular
signaling and are relevant to cancer (Garcia-Echeverria) and
chronic inflammatory diseases (Bhagwat). The search for
novel kinase inhibitors, which has become the focus of recent
drug discovery efforts, has yielded eight small molecule
drugs and a handful of protein therapeutics approved for
human use to date. The number of kinase inhibitor drugs for
the treatment of human disease is likely to increase in the
near future. Also, the volume describes novel inhibitors of
nucleotidase enzymes that interconvert extracellular nucleo-
tides (Baki et al.), leading to a spectrum of biological effects.
In conclusion, these fields deriving from the purinome have
become a major focus in the pharmaceutical industry, and the
promise of new drugs emerging from them is enormous. We
hope that this special issue will be a good source of information
and reference for basic and applied researchers in this field.
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